Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 4
1984 7
1985 6
1986 7
1987 10
1988 3
1989 3
1990 2
1991 4
1992 8
1993 15
1994 13
1995 7
1996 15
1997 10
1998 9
1999 5
2000 10
2001 3
2002 6
2003 6
2004 10
2005 8
2006 7
2007 6
2008 10
2009 8
2010 15
2011 3
2012 9
2013 17
2014 12
2015 13
2016 10
2017 9
2018 21
2019 15
2020 23
2021 16
2022 18
2023 13
2024 8
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Results by year

Filters applied: . Clear all
Page 1
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference.
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Levey AS, et al. Among authors: mittelman m. Kidney Int. 2020 Jun;97(6):1117-1129. doi: 10.1016/j.kint.2020.02.010. Epub 2020 Mar 9. Kidney Int. 2020. PMID: 32409237 Free article.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Cheson BD, et al. Among authors: mittelman m. Blood. 2006 Jul 15;108(2):419-25. doi: 10.1182/blood-2005-10-4149. Epub 2006 Apr 11. Blood. 2006. PMID: 16609072 Free article.
How we diagnose Myelodysplastic syndromes.
Oster HS, Mittelman M. Oster HS, et al. Among authors: mittelman m. Front Oncol. 2024 Sep 13;14:1415101. doi: 10.3389/fonc.2024.1415101. eCollection 2024. Front Oncol. 2024. PMID: 39346739 Free PMC article. Review.
Humanized mouse models in MDS.
Munteanu R, Gulei D, Moldovan CS, Azzoni E, Belver L, Feder R, Pirv S, Buzoianu AD, Einsele H, Mittelman M, Ghiaur G, Hasserjian R, Tomuleasa C. Munteanu R, et al. Among authors: mittelman m. Cell Death Dis. 2025 Jul 17;16(1):531. doi: 10.1038/s41419-025-07861-0. Cell Death Dis. 2025. PMID: 40675972 Free PMC article. Review.
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT.
Gurnari C, Robin M, Adès L, Aljurf M, Almeida A, Duarte FB, Bernard E, Cutler C, Della Porta MG, De Witte T, DeZern A, Drozd-Sokolowska J, Duncavage E, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian R, Hellström-Lindberg E, Jacoby M, Kulasekararaj A, Lindsley RC, Maciejewski JP, Makishima H, Malcovati L, Mittelman M, Myhre AE, Ogawa S, Onida F, Papaemmanuil E, Passweg J, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso MT, Yakoub-Agha I, Zeidan A, Walter M, Kröger N, McLornan DP, Cazzola M. Gurnari C, et al. Among authors: mittelman m. Blood. 2025 May 1;145(18):1987-2001. doi: 10.1182/blood.2024025131. Blood. 2025. PMID: 39970324
Sunbed lentigines.
Mittelman M, Dave HP, Gutman PD, Schechter AN. Mittelman M, et al. BMJ. 1988 Jul 2;297(6640):66. doi: 10.1136/bmj.297.6640.66-b. BMJ. 1988. PMID: 3408916 Free PMC article. No abstract available.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
385 results